milestone payments

Esperion Therapeutics shares surge following $1.1B Archimed acquisition announcement at $3.16 per share plus contingent value rights.

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.

Liberty Gold sells Goldstrike Project to Heliostar Metals for $72.5M, redirecting capital toward flagship Black Pine Oxide development in Idaho.

Aligos Therapeutics licenses pevifoscorvir to Xiamen Amoytop for Greater China development, receiving $25M upfront and up to $420M in milestones.

Telix Pharma secures $2.14B partnership with Regeneron for solid tumor radiopharmaceuticals while reporting 11% quarterly revenue growth and FDA acceptance of brain cancer imaging application.

Eli Lilly acquires Centessa Pharmaceuticals, which developed sleep-disorder treatments with Nxera Pharma. Nxera retains royalties, milestones, and equity stake.

Eli Lilly acquires Centessa Pharmaceuticals, developer of OX2R agonists for sleep disorders co-created with Nxera Pharma, which retains milestone payments and royalties.

XOMA Royalty reports $50M+ cash receipts in 2025, with royalties up 68% YoY. Company adds 22 assets, completes seven acquisitions, and repurchases $16M in shares.

NuScale stock plunged 79% to $12 despite NRC certification, facing execution risks and $6B in contingent partnership obligations before generating material revenue.

Tenaya Therapeutics surges 31% after partnering with Alnylam on cardiovascular genetic targets, securing $10M upfront and $1.13B in potential milestone payments.